Waldenström's macroglobulinemia overview

Jump to navigation Jump to search

Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Waldenström's macroglobulinemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Waldenström's macroglobulinemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Waldenström's macroglobulinemia overview

CDC on Waldenström's macroglobulinemia overview

Waldenström's macroglobulinemia overview in the news

Blogs on Waldenström's macroglobulinemia overview

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Waldenström's macroglobulinemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Overview

Waldenström macroglobulinemia is a cancer involving subtype of white blood cells called lymphocytes. The main attributing antibody is IgM. It is a type of lymphoproliferative disease, and shares clinical characteristics with the indolent non-Hodgkin lymphomas.[1]

Historical Perspective

Waldenström's macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 1944.[2]

Classification

Waldenström's macroglobulinemia is classified as a subtypes of Non-Hodgkin Lymphoma according to the new World Health Organization and the Revised European American Lymphoma (REAL) classifications.[2][3]

Pathophysiology

Waldenström Macroglobulinemia is uncontrolled clonal proliferation of terminally differentiated B lymphocytes, which are normally involved in humoral immunity.[2] Genes involved in pathogenesis of Waldenström Macroglobulinemia include MYD88-L265P, CXCR4 and chromosomes 6q, 13q, 3q, 6p and 18q.[4] The progression to Waldenström Macroglobulinemia usually involves the MYD88/IRAK, PI3K/Akt/mTOR molecular pathway. [5]

Causes

Common causes of Waldenström's macroglobulinemia include genetic, environmental, and autoimmune factors.[6][7]

Differentiating Waldenström's macroglobulinemia from other B cell lymphoid neoplasms

Waldenström's macroglobulinemia must be differentiated from Multiple myeloma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, Follicular lymphoma, Mantle cell lymphoma, and Marginal zone lymphoma. [4]

Epidemiology and Demographics

The prevalence of Waldenström's macroglobulinemia is estimated to be 1500 cases in United States annually. Waldenström's macroglobulinemia represents 1% of all hematological cancers.[6]

Risk factors

Common risk factors in the development of Waldenström's macroglobulinemia are Monoclonal gammopathy of undetermined significance, age >50 year old, white ethnicity, hereditary, hepatitis C, and immune disorders.[8]

Screening

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for Waldenström's macroglobulinemia.[9]

Natural History, Complications and Prognosis

If left untreated, patients with asymptomatic Waldenström's macroglobulinemia may progress to develop symptomatic disease. Common complications of Waldenström's macroglobulinemia include hyperviscosity syndrome, cold haemagglutinin disease, cryoglobulinemia, peripheral neuropathy, venous thromboembolism, primary amyloidosis, heart failure, malabsorbtive diarrhea, and bleeding manifestations. Prognosis varies depending on the prognostic factors involved. Five year survival rate is 87% for low-risk disease and 36% for high-risk disease. [10]

History and symptoms

The hallmark of Waldenström's macroglobulinemia is hyperviscosity syndrome. A positive history of oronasal bleeding and peripheral neuropathy is suggestive of Waldenström's macroglobulinemia.[11]

Physical Examination

Patients with Waldenström's macroglobulinemia usually appear oriented to time, place, and person. Physical examination of patients with Waldenström's macroglobulinemia is usually remarkable for various findings depending on degree of tissue infiltration by malignant tumor cells, hyperviscosity syndrome, and accumulation of paraprotein.[12]

Laboratory Findings

Elevated Beta-2-microglobulin and abnormal coagulation studies are diagnostic of Waldenström's macroglobulinemia. [13]

Bone marrow aspiration and biopsy

Bone marrow aspirate is frequently hypocellular in Waldenström's macroglobulinemia. Biopsy specimen is usually hypercellular and infiltrated with lymphoid and plasmacytoid cells. Dutcher bodies (PAS positive Intranuclear vacuoles containing IgM monoclonal protein) are characteristic feature of Waldenström's macroglobulinemia.[14]

Electrophoresis and Immunofixation

In Waldenström's macroglobulinemia, Serum and urine protein electrophoresis is used as the screening test, while Serum and urine immunofixation is used as the confirmatory test.[14]

Chest x-ray

On chest x-ray, Waldenström's macroglobulinemia may be characterized by pulmonary infiltrates, nodules, effusion, and congestive heart failure.[13]

CT scan

CT scan imaging of chest, abdomen, and pelvis may show evidence of adenopathy, and hepatomegaly.[13]

MRI

MRI of the spine may show bone marrow involvement. [13]

Other Diagnostic Studies

Patients with Waldenström's macroglobulinemia should have nerve conduction study and antimyelin associated glycoprotein serology done.[14]

Medical Therapy

Risk stratification determines the protocol of management used for Waldenström's macroglobulinemia patients. Watchful waiting is recommended for asymptomatic Waldenström's macroglobulinemia. Symptomatic Waldenström's macroglobulinemia is treated with Rituximab +/- Chemotherapy.[15]

References

  1. Cheson BD (2006). "Chronic Lymphoid Leukemias and Plasma Cell Disorders". In Dale DD, Federman DD. ACP Medicine. New York, NY: WebMD Professional Publishing. ISBN 0974832715.
  2. 2.0 2.1 2.2 Waldenström's macroglobulinemia. Wikipedia (2015)https://en.wikipedia.org/wiki/Waldenström%27s_macroglobulinemia#Pathophysiology Accessed on November 6, 2015
  3. Waldenström's macroglobulinemia. International Waldenström's macroglobulinemia Foundation (2015)http://www.iwmf.com/sites/default/files/docs/WM_Review_Ghobrial_Jan2014.pdf Accessed on November 9, 2015
  4. 4.0 4.1 Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenström macroglobulinemia. UpToDate (2015)http://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-manifestations-and-diagnosis-of-waldenstrom-macroglobulinemia?source=see_link Accessed on November 9, 2015
  5. Waldenström macroglobulinemia. International Waldenström Macroglobulinemia foundation (2015)http://www.iwmf.com/sites/default/files/docs/WM_Review_Ghobrial_Jan2014.pdf Accessed on November 12, 2015
  6. 6.0 6.1 Waldenström's macroglobulinemia. Wikipedia (2015). https://en.wikipedia.org/wiki/Waldenström%27s_macroglobulinemia#cite_note-19 Accessed on November 6, 2015
  7. Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenström macroglobulinemia. UpToDate (2015). http://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-manifestations-and-diagnosis-of-waldenstrom-macroglobulinemia#H3 Accessed on November 6, 2015
  8. Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
  9. Recommendations. US preventive services task force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=medulloblastoma Accessed on November 10, 2015
  10. Waldenström's macroglobulinemia. Patient (2015)http://patient.info/doctor/waldenstroms-macroglobulinaemia-pro Accessed on November 10, 2015
  11. Waldenström's macroglobulinemia. UpToDate (2015)http://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-manifestations-and-diagnosis-of-waldenstrom-macroglobulinemia?source=machineLearning&search=Waldenström%27s+macroglobulinemia&selectedTitle=1%7E80&sectionRank=3&anchor=H29#H6 Accessed on November 10, 2015
  12. Waldenström's macroglobulinemia. Medscape (2015)http://emedicine.medscape.com/article/207097-overview#a3 Accessed on November 10, 2015
  13. 13.0 13.1 13.2 13.3 Waldenström's macroglobulinemia. Medscape (2015)http://emedicine.medscape.com/article/207097-workup#c7 Accessed on November 10, 2015
  14. 14.0 14.1 14.2 Waldenström's macroglobulinemia. UpToDate (2015)http://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-manifestations-and-diagnosis-of-waldenstrom-macroglobulinemia?source=machineLearning&search=Waldenström%27s+macroglobulinemia&selectedTitle=1%7E80&sectionRank=3&anchor=H29#H18 Accessed on November 10, 2015
  15. Waldenström's macroglobulinemia. Medscape (2015)http://emedicine.medscape.com/article/2057687-overview Accessed on November 11, 2015

Template:WH Template:WS